ALX Oncology Holdings Earnings Preview: Analyst Estimates and Past Performance
ByAinvest
Tuesday, Aug 12, 2025 8:07 pm ET2min read
ALXO--
ALX Oncology Holdings Inc. (ALXO) is set to release its Q2 2024 earnings report on August 12, 2025. Analysts anticipate an earnings per share (EPS) of $-0.37 [2]. The company's EPS missed by $0.14 in Q1 2025, resulting in an 8.24% drop in share price [2]. Over the last 52-week period, shares have fallen by 76.14% [2].
The earnings report is expected to have a significant impact on ALXO's stock price. Investors are hopeful for positive guidance for the next quarter, which could potentially provide clarity on the company's financial health and future prospects.
ALX Oncology Holdings reported a quarterly adjusted loss of 43 cents per share for the quarter ended June 30, 2025, which was higher than the same quarter last year when the company reported EPS of -76 cents [1]. The mean expectation of five analysts for the quarter was for a loss of 45 cents per share. Wall Street expected results to range from -53 cents to -39 cents per share.
The company reported a quarterly loss of $25.95 million. Analysts had forecasted zero revenue, which matches the reported revenue [1]. The company's reported EPS for the quarter was a loss of 49 cents [1].
ALX Oncology Holdings shares have risen by 48.0% this quarter and lost 63.2% so far this year [1]. The current average analyst rating on the shares is "buy," with 5 "strong buy" or "buy," 1 "hold," and no "sell" or "strong sell" recommendations [1]. Wall Street's median 12-month price target for ALX Oncology Holdings Inc. is $2.50, about 75.4% above its last closing price of $0.61 [1].
The mean earnings estimate of analysts has fallen by about 4.7% in the last three months, but there have been no earnings estimate revisions by analysts covering the company in the last 30 days [1].
ALX Oncology Holdings' stock price gained 0.0976% on Tuesday, August 12, 2025, rising from $0.615 to $0.615 [3]. The stock lies in the middle of a very wide and strong rising trend in the short term and is expected to rise 23.92% during the next 3 months with a 90% probability [3].
The stock holds a sell signal from the short-term Moving Average but a buy signal from the long-term average, indicating a general buy signal in the stock [3]. The stock is expected to rise 23.92% during the next 3 months and hold a price between $0.588 and $0.88 at the end of this 3-month period [3].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U422H:0-alx-oncology-holdings-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.benzinga.com/insights/earnings/25/08/47040030/alx-oncology-holdingss-earnings-a-preview
[3] https://stockinvest.us/stock/ALXO
ALX Oncology Holdings (ALXO) is set to release its Q2 2024 earnings report on August 12, 2025. Analysts expect an EPS of $-0.37. The company's EPS missed by $0.14 in Q1 2025, leading to an 8.24% drop in share price. Over the last 52-week period, shares are down 76.14%. The announcement is expected to have a significant impact on the company's stock price, with investors hoping to hear positive guidance for the next quarter.
Title: ALX Oncology Holdings (ALXO) Q2 2024 Earnings Report: Analysts Expect EPS of $-0.37ALX Oncology Holdings Inc. (ALXO) is set to release its Q2 2024 earnings report on August 12, 2025. Analysts anticipate an earnings per share (EPS) of $-0.37 [2]. The company's EPS missed by $0.14 in Q1 2025, resulting in an 8.24% drop in share price [2]. Over the last 52-week period, shares have fallen by 76.14% [2].
The earnings report is expected to have a significant impact on ALXO's stock price. Investors are hopeful for positive guidance for the next quarter, which could potentially provide clarity on the company's financial health and future prospects.
ALX Oncology Holdings reported a quarterly adjusted loss of 43 cents per share for the quarter ended June 30, 2025, which was higher than the same quarter last year when the company reported EPS of -76 cents [1]. The mean expectation of five analysts for the quarter was for a loss of 45 cents per share. Wall Street expected results to range from -53 cents to -39 cents per share.
The company reported a quarterly loss of $25.95 million. Analysts had forecasted zero revenue, which matches the reported revenue [1]. The company's reported EPS for the quarter was a loss of 49 cents [1].
ALX Oncology Holdings shares have risen by 48.0% this quarter and lost 63.2% so far this year [1]. The current average analyst rating on the shares is "buy," with 5 "strong buy" or "buy," 1 "hold," and no "sell" or "strong sell" recommendations [1]. Wall Street's median 12-month price target for ALX Oncology Holdings Inc. is $2.50, about 75.4% above its last closing price of $0.61 [1].
The mean earnings estimate of analysts has fallen by about 4.7% in the last three months, but there have been no earnings estimate revisions by analysts covering the company in the last 30 days [1].
ALX Oncology Holdings' stock price gained 0.0976% on Tuesday, August 12, 2025, rising from $0.615 to $0.615 [3]. The stock lies in the middle of a very wide and strong rising trend in the short term and is expected to rise 23.92% during the next 3 months with a 90% probability [3].
The stock holds a sell signal from the short-term Moving Average but a buy signal from the long-term average, indicating a general buy signal in the stock [3]. The stock is expected to rise 23.92% during the next 3 months and hold a price between $0.588 and $0.88 at the end of this 3-month period [3].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U422H:0-alx-oncology-holdings-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.benzinga.com/insights/earnings/25/08/47040030/alx-oncology-holdingss-earnings-a-preview
[3] https://stockinvest.us/stock/ALXO
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet